SavedAdd your journal

Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 4

Metoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effect

Zeynep GUNES OZUNAL
Yaprak DONMEZ CAKİL
Sena TEKİN
Esra SAGLAM
Ranan AKTAS
Pages
1188–1192
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Safety concerns about its use in hepatocellular cancer should be addressed in clinical trials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractAim: Metoclopramide is an antiemetic drug used for treating postoperative or chemotherapy-induced emesis.
📊
Key Findings & Data:The study aims to investigate the effect of metoclopramide on hepatocellular cancer cell proliferation alone or in combination with sorafenib.Material and Methods: Metoclopramide doses of 0.17 µM to 25 µM alone or in combination with sorafenib were administered to human hepatocellular cancer cell line, HepG2.
💡
Conclusion & Impact:Safety concerns about its use in hepatocellular cancer should be addressed in clinical trials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AbstractAim: Metoclopramide is an antiemetic drug used for treating postoperative or chemotherapy-induced emesis. Sorafenib is a kinase inhibitor drug and is approved for the treatment of advanced primary liver cancer, renal cell carcinoma, thyroid cancer, and acute myeloid leukemia. Hepatocellular cancer is a common cause of cancer-related death and its treatment may require coadministration of an antiemetic medication. The study aims to investigate the effect of metoclopramide on hepatocellular cancer cell proliferation alone or in combination with sorafenib.Material and Methods: Metoclopramide doses of 0.17 µM to 25 µM alone or in combination with sorafenib were administered to human hepatocellular cancer cell line, HepG2. Cell viability and proliferation test was used to determine the possible effects on proliferation. Hematoxylin and Eosin staining was performed to visualize the morphological effects of the treatments.Results: Metoclopramide doses of 0.58 µM, 25µM increased cell proliferation when compared to the control group. Metoclopramide combination groups with 9.9 µM sorafenib were compared with control and sorafenib groups. Each combination group was comparable with the control group.Conclusion: Metoclopramide increased proliferation in certain doses. Sorafenib inhibited the effect. Safety concerns about its use in hepatocellular cancer should be addressed in clinical trials.

🔖

Cite This Article

OZUNAL, Z. G., CAKİL, Y. D., TEKİN, S., SAGLAM, E., AKTAS, R. (2022). Metoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effect. Annals of Medical Research, Cilt: 27 - Sayı: 4, 1188–1192. https://ajindex.com/articles/446447

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Schulze-Delriu K. Drug therapy. Metoclopramide. N Eng J Med 1981;305:28-33
  2. Sharkey KA, MacNaughton WK. Gastrointestinal pharmacology. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13nd edition. New York: McGraw-Hill 2018;921-54
  3. Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol 2018;9:913
  4. Isola S, Adams N. Metoclopramide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. https://www.ncbi.nlm.nih.gov/books/ NBK519517/ access date: 24.03.2020 5. Balogh J, III DV, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53
  5. Pitoia F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther 2016;10:1119-31
  6. Liu T, Ivaturi V, Sabato P, et al. Sorafenib dose recommendation in acute myeloid leukemia based on exposure-FLT3 relationship. Clin Transl Sci 2018;11:435-43
  7. Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8
  8. Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006;333:324
  9. Rangwala F, Williams KP, Smith GR, et al. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 2012;12:402
  10. Motlagh PB, Henriksson R, Grankvist K. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Acta Oncol 1995;34:871-5
  11. Motlagh PB, Henriksson R, Grankvist K. Metoclopramide inhibits the cytotoxicity of cisplatin and enhances the cytotoxicity of epirubicin. Pharmacol Toxicol 1995;76:146-8
  12. Olsson AR, Hua J, Sheng Y, et al. Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. Acta Oncol 1997;36:323-30
  13. Lybak S, Pero RW. The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human peripheral mononuclear leukocytes at clinically relevant doses. Carcinogenesis 1991;12:1613-7
  14. Zerek-Mele